» Articles » PMID: 20385723

Clinical, Hormonal and Molecular Characterization of Pituitary ACTH Adenomas Without (silent Corticotroph Adenomas) and with Cushing's Disease

Overview
Specialty Endocrinology
Date 2010 Apr 14
PMID 20385723
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Silent corticotroph adenomas (SCAs) are rare pituitary tumours immunoreactive for ACTH, but without clinical evidence of Cushing's disease. We characterized SCAs based on clinical, hormonal and molecular data, and compared the characteristics of these tumours with those of macro (MCA)- and micro (mCA)-ACTH adenomas with Cushing's disease.

Methods: Fifty ACTH adenomas (14 SCAs, 15 MCAs and 21 mCAs) with complete corresponding clinical, radiological and biochemical data were selected. Histological corticotroph differentiation; immunostaining for ACTH, beta-endorphin and beta-LPH; and mRNA expression levels of TPIT, POMC, GRalpha, prohormone convertase 1/3 (PC1/3) and galectin-3 were compared in 21 representative tumours.

Results: Despite the absence of clinical hypercortisolism in patients with SCA, elevated plasma ACTH levels that were similar to those associated with mCA were observed. The cortisol/ACTH ratio was similar between SCA and MCA groups and lower than that found with mCA (P<0.05). This dissociation could be explained by lower expression of PC1/3 in SCA and MCA than in mCA (P<0.05). After an i.v. dexamethasone suppression test, ACTH levels were significantly higher in patients with MCA than in those with mCA (P<0.05). Cytological and immunocytochemical analyses as well as mRNA expression levels of TPIT, POMC and GRalpha confirmed corticotroph differentiation in both mCAs and MCAs and in half of the SCAs, with a strong correlation between TPIT and POMC mRNA expression levels in SCAs (R(2)=0.72; P<0.01) and in MCAs (R(2)=0.65; P<0.05).

Conclusions: Despite the absence of hypercortisolism, SCAs exhibit histological, biochemical and molecular corticotroph differentiation. SCA and MCA show hormonal and molecular similarities differentiating them from mCA.

Citing Articles

The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors.

Casar-Borota O, Burman P, Lopes M Brain Pathol. 2024; 35(1):e13302.

PMID: 39218431 PMC: 11669403. DOI: 10.1111/bpa.13302.


Phenotype Transformation of PitNETs.

Li Z, Wu Y, He G, Wang R, Bao X Cancers (Basel). 2024; 16(9).

PMID: 38730682 PMC: 11083144. DOI: 10.3390/cancers16091731.


Trouillas's Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach.

Calandrelli R, Mattogno P, Chiloiro S, Gessi M, DApolito G, Tartaglione T Diagnostics (Basel). 2024; 14(3).

PMID: 38337790 PMC: 10855691. DOI: 10.3390/diagnostics14030274.


The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.

Kober P, Rusetska N, Mossakowska B, Maksymowicz M, Pekul M, Zielinski G Front Endocrinol (Lausanne). 2023; 14:1124646.

PMID: 37065760 PMC: 10090509. DOI: 10.3389/fendo.2023.1124646.


Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression.

Demarchi G, Perrone S, Esper Romero G, De Bonis C, Casasco J, Sevlever G Front Endocrinol (Lausanne). 2022; 13:870172.

PMID: 35928898 PMC: 9344046. DOI: 10.3389/fendo.2022.870172.